(UroToday.com) In a plenary session entitled “Advances in Prostate Cancer: Androgen Deprivation Therapy Across the Disease Continuum” held in conjunction with the American Urologic Association Annual Meeting, Dr. Alicia Morgans explored the role of systemic treatment intensification in metastatic castration sensitive prostate cancer (mCPSC).
(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. In particular, agents with demonstrated survival benefits later in the natural history of prostate cancer have been used earlier in the disease process. In the context of metastatic castration resistant prostate cancer (mCRPC), docetaxel was the first agent to demonstrate a survival benefit when combined […]
(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. In particular, agents with demonstrated survival benefits later in the natural history of prostate cancer have been used earlier in the disease process. In the context of metastatic castration-resistant prostate cancer (mCRPC), docetaxel was the first agent to demonstrate a survival benefit when combined […]
(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. In the context of metastatic castration-resistant prostate cancer (mCRPC), docetaxel was the first agent to demonstrate a survival benefit when combined with conventional androgen deprivation therapy (ADT). Following this, a number of other treatment approaches have been assessed and are now clinically used including androgen […]
(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. In the context of metastatic castration resistant prostate cancer (mCRPC), docetaxel was the first agent to demonstrate a survival benefit when combined with conventional androgen deprivation therapy (ADT). Following this, a number of other treatment approaches have been assessed and are now clinically used including […]
(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. In the context of metastatic castration resistant prostate cancer (mCRPC), docetaxel was the first agent to demonstrate a survival benefit when combined with conventional androgen deprivation therapy (ADT). Following this, a number of other treatment approaches have been assessed and are now clinically used including […]
(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. In particular, agents with demonstrated survival benefits later in the natural history of prostate cancer have been used earlier in the disease process. In the context of metastatic castration resistant prostate cancer (mCRPC), docetaxel was the first agent to demonstrate a survival benefit when combined […]
(UroToday.com) In the Society of Urologic Oncology plenary session held at the American Urologic Association Annual Meeting, Dr. Ronald Chen addressed the question of designing the ideal randomized controlled trial in high-risk localized prostate cancer.
(UroToday.com) In the Society of Urologic Oncology (SUO) plenary session held at the American Urologic Association (AUA) Virtual Annual Meeting, Dr. Zachary Klaassen addressed the question of suicidality in urologic cancer patients. After many years of little attention, there has been increasing interest in understanding the mental health of patients with cancer. Dr. Klaassen began by […]
(UroToday.com) In the Society of Urologic Oncology plenary session held at the American Urologic Association Annual Meeting, Dr. Kelvin Moses addressed controversies in the management of high-risk prostate cancer.
